|
|
|
| Advances in targeted drug therapy for brain metastasis of non-small cell lung cancer |
| LI Wen′ge GE Wei |
| Department of Oncology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
Abstract The most common distant metastasis of lung cancer is in the brain. Currently, the treatment methods for brain metastasis of non-small cell lung cancer (NSCLC) include chemotherapy, radiotherapy, molecular targeted therapy and immunotherapy. For patients with brain metastasis with specific driver gene mutations, molecular targeted drugs have achieved significant effects, among which targeted drugs combined with stereotactic radiotherapy can significantly improve the intracranial remission rate, progression-free survival and total survival time of patients. At present, the acquired drug resistance and post-treatment progress of first-line targeted drugs are the main problems in clinical practice. In this review, molecular targeting therapy for brain metastasis of NSCLC and its current status and progress are reviewed.
|
|
|
|
|
|
[1] Miller KD，Nogueira L，Mariotto AB，et al. Cancer treatment and survivorship statistics，2019 [J]. CA Cancer J Clin，2019，69（5）：363-385.
[2] Pedrosa RMSM，Mustafa DAM，Aerts JGJV，et al. Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis [J]. Front Oncol，2018，8：159.
[3] Xu J，Du Y，Liu XJ，et al. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy [J]. Pharmacol Res，2017，126：66-76.
[4] Shi Y，Au JS，Thongprasert S，et al. A prospective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology（PIONEER） [J]. J Thorac Oncol，2014，9（2）：154-162.
[5] 王恩华，朱明华，步宏，等.非小细胞肺癌靶向药物治疗相关基因检测的规范建议[J].中华病理学杂志，2016（2）：73-77.
[6] Phan TT，Tran BT，Nguyen ST，et al. EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer [J]. Clin Transl Med，2019，8（1）：4.
[7] Arbour KC，Kris MG，Riely GJ，et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases [J]. Cancer，2018，124（1）：105-109.
[8] Tan J，Li M，Zhong W，et al. Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC：A direct comparative analysis of icotinib，gefitinib，and erlotinib in a nude mouse model [J]. Oncotarget，2017，8（58）：98771-98781.
[9] Wei YF，Lim CK，Tsai MS，et al. Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases [J]. Clin Lung Cancer，2019，20（3）：e274-e283.
[10] Schuler M，Wu YL，Hirsh V，et al. First Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases [J]. J Thorac Oncol，2016，11（3）：380-390.
[11] Goss G，Tsai CM，Shepherd FA，et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer（AURA2）：a multicentre，open-label，single-arm，phase 2 study [J]. Lancet Oncol，2016，17（12）：1643-1652.
[12] Soria JC，Ohe Y，Vansteenkiste J，et al. Osimertinib in Untreated EGFR-Mutated Advanced Non - Small - Cell Lung Cancer [J]. N Engl J Med，2018，378（2）：113-125.
[13] Koba T，Kijima T，Takimoto T，et al. Rapid intracranial response to osimertinib，without radiotherapy，in nonsmall cell lung cancer patients harboring the EGFR T790M mutation：Two Case Reports [J]. Medicine (Baltimore)，2017，96（6）：e6087.
[14] He ZY，Li MF，Lin JH，et al. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases：a retrospective cohort study [J]. Cancer Manag Res，2019，11：2129-2138.
[15] Barlesi F，Mazieres J，Merlio JP，et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer：results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup（IFCT）[J]. Lancet，2016，387（10026）：1415-1426.
[16] Dagogo-Jack I，Shaw AT. Crizotinib resistance：implications for therapeutic strategies [J]. Ann Oncol，2016， 27 Suppl 3:iii42-iii50.
[17] Tomasini P，Egea J，Souquet-Bressand M，et al. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer：clinical trial evidence and experience with a focus on brain metastases [J]. Ther Adv Respir Dis，2019，13：1753466619831906.
[18] Hida T，Nokihara H，Kondo M，et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer （J-ALEX）：an open-label，randomised phase 3 trial [J]. Lancet，2017，390（10089）：29-39.
[19] Nishio M，Nakagawa K，Mitsudomi T，et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer [J]. Lung Cancer，2018，121：37-40.
[20] Peters S，Camidge DR，Shaw AT，et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer [J]. N Engl J Med，2017，377（9）：829-838.
[21] Mcleer-Florin A，Duruisseaux M，Pinsolle J，et al. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer [J]. Lung cancer，2018，116：15-24.
[22] Frezzetti D，Gallo M，Maiello MR，et al. VEGF as a potential target in lung cancer [J]. Expert Opin Ther Targets，2017，21（10）：959-966.
[23] Besse B，Le Moulec S，Mazières J，et al. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic，Untreated Brain Metastases （BRAIN）：A Nonrandomized，Phase II Study [J]. Clin Cancer Res，2015，21（8）：1896-1903.
[24] Lévy C，Allouache D，Lacroix J，et al. REBECA：a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours [J]. Ann Oncol，2015，26（11）：2359.
[25] Brastianos PK，Carter SL，Santagata S，et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets [J]. Cancer Discov，2015，5（11）：1164-1177. |
|
|
|
